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Non-small-cell lung cancer (NSCLC) is the leading cause of death from cancer for both
men and women. Chemotherapy is the mainstay of treatment in advanced disease, but
is only marginally effective. In about 30% of patients with advanced NSCLC in East Asia
and in 10–15% in Western countries, epidermal growth factor receptor (EGFR) mutations
are found. In this population, first-line treatment with the tyrosine kinase inhibitors (TKIs)
erlotinib, gefitinib, or afatinib is recommended. The treatment beyond progression is less
well-defined. In this paper, we present three patients, EGFR mutation positive, with local
progression after an initial treatment withTKI.These patients were treated with local radio-
therapy.TKI was temporarily stopped and restarted after radiotherapy.We give an overview
of the literature and discuss the different treatment options in case of progression afterTKI:
TKI continuation with or without chemotherapy, TKI continuation with local therapy, alter-
native dosing or switch to next-generation TKI or combination therapy. There are different
options for treatment beyond progression in EGFR mutation positive metastatic NSCLC,
but the optimal strategy is still to be defined. Further research on this topic is ongoing.
Keywords: advanced non-small-cell lung cancer, EGFR mutation, local progression, radiotherapy, tyrosine kinase
inhibitor
INTRODUCTION: CASE REPORTS
The first case concerns a 56 years old woman with a smoking his-
tory of 19 pack years (PY). In October 2011, she was diagnosed
with a metastatic adenocarcinoma of the lung, epidermal growth
factor receptor (EGFR) mutation positive with a deletion found
on exon 19. The primary tumor was located in the left upper lobe
(Figure 1A). There was a pericardial effusion that was proven to
be metastatic.
In December 2011, the tyrosine kinase inhibitor (TKI) gefitinib
(Iressa®) was started. The first follow up CT scan, 2 months after
starting Iressa showed near complete response (Figure 1B).
In March 2013, 18 months after initial diagnosis, local progres-
sion is documented on the site of the primary tumor (Figure 1C)
and staging by PET-CT showed no metastatic lesions. On the
multidisciplinary oncology board, it was decided to give local
stereotactic body radiotherapy (3 Gy× 20 Gy), which was started
in April 2013. TKI treatment was temporarily stopped during
radiotherapy. Three months after treatment a significant decrease
of the tumor was seen (Figure 1D). Until October 2014, 17 months
after completion of the radiotherapy, there is no evidence of disease
and the patient continues TKI treatment.
The second case concerns a 66 years old male ex-smoker (6
PY during adolescence). In May 2010, an EGFR mutation (L858R
c.2573T>G) positive adenocarcinoma of the right lower lobe of
the lung with metastasis in the contra-lateral lung was diagnosed
(Figure 2A). In June 2010, afatinib, a irreversible EGFR-HER2-
inhibitor, was started in a clinical trial (Gilotrif® in BIBW 2992
trial). The patient experienced partial response (Figure 2B) until
July 2012, 26 months after initial diagnosis. At that point, local
progression was seen at the site of the primary tumor in the right
upper lobe, and no distant metastases (Figure 2C). There was a
multidisciplinary consensus to start local hypofractionated radio-
therapy (20 Gy× 3 Gy) and stop TKI during this treatment. After
completion of the radiotherapy gefitinib was started. A signifi-
cant decrease of the tumor was seen (Figure 2D). One year later,
in June 2013, a new pleural effusion was seen and proven to be
metastatic disease. A switch to standard chemotherapy was initi-
ated in October 2013 after pleurodesis. We note stable disease until
April 2014. At that point, erlotinib was started because of progres-
sive disease. Four months later, brain metastasis were diagnosed
which where treated with whole brain radiotherapy (5 Gy× 4 Gy).
Erlotinib was continued afterwards. Until October 2014, we note
stable disease.
The third case concerns a 59 years old female never smoker. In
January 2009, she was diagnosed with an adenocarcinoma of the
lung (left upper lobe) with bone and liver metastasis (Figure 3A).
The tumor was EGFR mutation positive, with a deletion found
on exon 19. In February, erlotinib was started in a clinical trial
(FIELT study) with near complete remission (Figure 3B). 18F-
FDG PET-CT showed no distant metastases. After 34 months, the
FIELT study was closed. At that point, in December 2011, we made
a switch to gefitinib because erlotinib was not yet reimbursed in
first-line treatment. In May 2012, 6 months after switch to gefi-
tinib progression of the tumor in the left upper lobe was seen
(Figure 3C) and local stereotactic body radiotherapy was given
(8 Gy× 7.5 Gy). Gefinitib was stopped during radiotherapy but
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FIGURE 1 | (A) Tumor upper left lobe on diagnosis (CT scan). (B) Near
complete response 2 months after start TKI (CT scan). (C) Local progression
18 months after diagnosis (CT scan). (D) Partial response 3 months after
local stereotactic radiotherapy (CT scan).
FIGURE 2 | (A) Tumor lower right lobe on diagnosis (CT scan). (B) Partial
response 22 months after start TKI (CT scan). (C) Local progression
26 months after diagnosis (CT scan). (D) Partial response 9 months after
local radiotherapy (CT scan).
restarted afterwards. A significant decrease of the tumor was seen
(Figure 3D).
Until October 2014, we note stable disease, 27 months after
local therapy.
FIGURE 3 | (A) Tumor left upper lobe on diagnosis (18F-FDG PET-CT scan).
(B) Near complete response 32 months after start TKI (18F-FDG PET-CT
scan). (C) Local progression 40 months after diagnosis (18F-FDG PET-CT
scan). (D) Partial response 8 months after local radiotherapy (CT scan).
BACKGROUND
EGFR MUTATION AND TYROSINE KINASE INHIBITORS
Non-small-cell lung cancer (NSCLC) is the leading cause of death
from cancer for both men and women. Chemotherapy is the
mainstay of treatment in advanced disease, but is only marginally
effective.
Epidermal growth factor inhibitors show promise in the
treatment of metastatic NSCLC.
Responsiveness to these drugs is seen particularly in women,
adenocarcinoma, non-smokers, and Asians. In the majority of
these responding patients, a somatic mutation of the EGFR gene
is found (1).
In 2004, EGFR mutations were described and characterized by
high activity of EGFR-TKIs such as gefitinib and erlotinib. EGFR
mutations are found in about 30% of patients with advanced
NSCLC in East Asia and in 10–15% in Western countries (1–3).
Epidermal growth factor receptor is a transmembrane receptor.
Its activation initiates a signal transduction cascade that pro-
motes tumor-cell proliferation, survival, and migration (Figure 4).
An activating mutation on the gene encoding for EGFR leads
to an upregulation of the EGFR, which results in uncontrolled
proliferation of tumor-cells, using the tyrosine kinase pathway.
Epidermal growth factor receptor or HER1 is a member of
the HER-family, a transmembrane peptide receptor family, with
tyrosine kinase activity. The HER-family comprises HER 1–4.
The TKI is a molecule that blocks binding of adenosine-5-
triphosphate (ATP) to the tyrosine kinase catalytic domain. This
interruption of the signaling pathway leads to massive apoptosis
of mutant tumor-cells.
Common alterations on the gene encoding for EGFR are exon
19 deletions and the L858R point mutation in exon 21, cov-
ering >90% of all mutations and sensitive to TKI. The other
EGFR mutations, e.g., the T790M mutation on exon 20, represent
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FIGURE 4 | Epidermal growth factor receptor pathway.
less than 10% of all mutations, and are associated with drug
resistance (1).
TREATMENT OF PATIENTS WITH ADVANCED NSCLC WITH EGFR
MUTATION
Both the European Society of Medical Oncology (ESMO) (2)
and the American College of Chest Physicians (ACCP) (3) rec-
ommend first-line treatment with a TKI (erlotinib or gefitinib)
in metastatic NSCLC bearing an activating EGFR mutation
because of higher response rate, longer progression free survival
(PFS), and better quality of life when compared with first-line
chemotherapy. These recommendations are based on five ran-
domized phase III trials that compared the efficacy of EGFR-TKI
vs. platinum based chemotherapy as first-line treatment (4–8)
(Table 1). In these trials, there was no statistical significant survival
advantage.
Also, afatinib, an irreversible TKI, showed a longer PFS in com-
parison with first-line chemotherapy in first-line treatment for
EGFR mutation positive NSCLC (9, 10) (Table 1). A pooled analy-
sis of two large open label phase III studies comparing afatinib with
chemotherapy showed significant improvement of overall survival
(OS) in patients with EGFR deletion 19. There was no significant
difference in OS for patients with L858R mutations (11).
The most common adverse events associated with EGFR
inhibitors are dermatologic toxicities, occurring in >50% of the
patients. A papulopustular rash is the most frequently reported
cutaneous side effect. Other reported cutaneous side effects are
xerosis, telangiectasia, fissures, hyperpigmentation, and hair and
nail changes. The papulopustular rash seems to be dose depen-
dent, with higher-grade of skin toxicity at higher dose levels. The
reaction is reversible, with usually a complete resolution within
4 weeks after ending treatment. In numerous studies, a correlation
between skin rash severity and response to EGFR-TKI treatment
was seen.
The incidence of diarrhea varies from 27 to 87% in phase III
clinical trials. Severe diarrhea can lead to dehydration, electrolyte
disturbances, and renal insufficiency.
Hepatitis or liver failure is rarely seen, but intermittent testing
of liver function is recommended (12, 13).
In general, EGFR-TKIs are better tolerated than chemotherapy.
This was documented in the quality of life analysis of the IPASS,
OPTIMAL, and LUX-LUNG 3–6 trial (4, 7, 9, 10).
EGFR MUTATION TESTING
European Society of Medical Oncology guidelines recommend
routine EGFR mutation testing in all non-squamous tumors in
patients with advanced or recurrent disease (14). EGFR testing
may be performed in selected cases of squamous tumors, guided
by clinical criteria (e.g., young age, minimal, or remote smok-
ing) and especially in the setting of more limited lung cancer
specimens (biopsy, cytology) in which an adenocarcinoma com-
ponent cannot be completely excluded (14, 15). The role of the
pathologist is not restricted to making a histological diagnosis,
with prudent use of immunohistochemistry in morphologically
undifferentiated cases of NSCLC, but he or she should also be
actively involved in sample reviewing, selection, and preparation
for DNA extraction for EGFR mutation testing. Mostly, formalin-
fixed, paraffin-embedded (FFPE) tissue is used, but also cytologic
samples (and particularly cell blocks),which account for up to 40%
of all NSCLC diagnoses, are suitable for EGFR mutation analysis
(14, 15). According to the CAP/IASCL/AMP molecular testing
guidelines, EGFR mutation tests should be able to detect muta-
tions in specimens with at least 50%, but ideally 10% tumor-cell
content. PCR-based methods are often preferred as they offer effi-
cient and sensitive assays allowing adequate internal and external
validation (15). ESMO and CAP/IASCL/AMP guidelines recom-
mend analysis of a wide coverage of mutations in exon 18–21,
including those associated with therapy resistance (14). Quality
control of these EGFR mutation tests is mandatory and labora-
tories performing these assays should enroll in external quality
assurance programs on a regular basis (14, 15). The pathology
department of our center used the Therascreen EGFR RGQ PCR
kit (Qiagen) to determine EGFR mutation status in the cases
described and obtained ISO15189 accreditation for this test since
May 2012.
As the number of biomarkers to be tested for lung cancer and
the number of targeted therapies are expected to increase in the
near future, new strategies are under development to allow testing
for multiple biomarkers on limited specimen volumes instead of
the single-target-gene approach of most traditional assays. Multi-
plex technologies such as next-generation sequencing are rapidly
evolving as a molecular diagnostic tool to meet these requirements
and are already implemented in daily routine practice (16).
INTRINSIC AND ACQUIRED RESISTANCE TO A TKI
There are two types of resistance: primary or intrinsic resistance,
occurring between the first and third month of treatment, and
secondary resistance or acquired resistance occurring later, after
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Table 1 | Phase III trials of EGFR tyrosine kinase inhibitors vs. chemotherapy as first-line treatment in patients with advanced NSCLC bearing
EGFR mutation.
Study n (EGFR mutation
positive patients)
EGFR-TKI Chemotherapy PFS median
(months)TKI vs.
chemotherapy
PFS hazard ratio
(95% CI)TKI vs.
chemotherapy
IPASS (4) 261 Gefitinib Carboplatin+paclitaxel 9.5 vs. 6.3 0.48 (0.36–0.64)
NEJ002 (5) 224 Gefitinib Carboplatin+paclitaxel 10.8 vs. 5.4 0.30 (0.22–0.41)
WJTOG3405 (6) 172 Gefitinib Cisplatin+paclitaxel 9.2 vs. 6.3 0.49 (0.34–0.71)
OPTIMAL (7) 154 Erlotinib Carboplatin+gemcitabine 13.1 vs. 4.6 0.16 (0.10–0.26)
EURTAC (8) 173 Erlotinib Cisplatin (or carboplatin+docetaxel
or gemcitabine
9.7 vs. 5.2 0.37 (0.25–0.54)
LUX-LUNG 3 (9) 345 Afatinib Cisplatin+pemetrexed 11.1 vs. 6.9 0.58 (0.43–0.78)
LUX-LUNG 6 (10) 364 Afatinib Cisplatin+gemcitabine 11 vs. 5.6 0.28 (0.20–0.39)
PFS, progression free survival; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor; CI, confidence interval.
an initial response to EGFR-TKI. Jackman et al. (17) defined sec-
ondary resistance with the following criteria: previous treatment
with a single-agent EGFR-TKI; either both of the following: a
tumor that harbors an EGFR mutation known to be associated
with drug sensitivity or objective clinical benefit from treatment
with an EGFR-TKI; systemic progression of disease (RECIST or
WHO) while on continuous treatment with gefitinib or erlotinib
within the last 30 days; and no intervening systemic therapy
between cessation of EGFR-TKI and initiation of new therapy
(Table 2).
The etiology of primary resistance is not well-known. Possi-
ble mechanisms are a false-positive test result for EGFR muta-
tion, resistant mutations or other downstream or parallel mol-
ecular abnormalities in the EGFR signaling pathway or mixed
tumors containing small cell components on initial diagnosis.
These resistant mutations or other downstream or parallel mol-
ecular abnormalities are similar to the mechanisms of acquired
resistance.
The mechanisms of acquired resistance can be divided in three
categories:
Genetic alterations in EGFR: secondary mutations and target gene
amplification
In approximately 50% of TKI-resistant, EGFR-mutant patients a
T790M mutation was found, which is a secondary mutation in
exon 20 of EGFR. The resistance is caused predominantly through
changes in ATP affinity. In EGFR-mutant tumors, the affinity for
ATP is reduced, but the addition of T790M leads to re-establishing
ATP as favored substrate rather than the TKI. Three, less frequent,
secondary EGFR mutations are described: D761Y, T854A, and
L747S.
Another cause of acquired resistance is EGFR gene amplifica-
tion, which may shift the intracellular balance between kinase and
TKI in favor of the kinase (20).
Bypass signaling
A pathway that bypasses the inhibited EGFR can also cause TKI
resistance. One well-described example is MET-amplification,
with an estimated frequency of 5–22% of TKI-resistant, EGFR-
mutant patients. MET-amplified subclones preexist in untreated
Table 2 | Criteria for acquired resistance to EGFR-TKI in lung cancer.
1. Prior therapy with a EGFR-TKI (monotherapy)
2. One of the two following
- Tumor with an EGFR mutation known to be associated with drug
sensitivity (e.g., exon 19 deletion, L858R, G719X)
- A documented partial or complete response or a significant and
prolonged stable disease, based on the RECIST or WHO criteria (18,
19), after treatment with a EGFR-TKI
3. Disease progression while on continuous treatment with EGFR-TKI
during the last 30 days
4. No additional systemic therapy since discontinuation of EGFR-TKI
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; RECIST,
response evaluation criteria in solid tumors (18); WHO, World Health Organiza-
tion (19).
tumor cells, but can cause resistance as MET-amplification occurs
as a result of selective pressure. Activation of MET through its
ligand, hepatocyte growth factor (HGF), may also promote resis-
tance. Other known bypass signaling tracts are HER-2 amplifica-
tion, BRAF mutations, and PIK3CA mutations (20).
Phenotypic alterations
Several reports describe transformations of EGFR-mutant NSCLC
to small-cell lung cancer (SCLC) or high-grade neuroendocrine
carcinoma.
The underlying mechanism is not known (20).
Other considerations
The combination of different resistance mechanisms is possible
within the same biopsy specimen or in specimen from differ-
ent tumor localizations within the same patient. This can lead
to disease “flare” on TKI discontinuation, because the pressure on
sensitive tumor cells is removed.
We also have to take in account the pharmacokinetic mecha-
nisms (e.g., influence of smoking, proton pump inhibitor intake,
concomitant food intake, concomitant use of CYP3A4 inhibitors
or inductors) and bad compliance, when intrinsic or acquired
resistance is suspected (20).
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DISCUSSION: TREATMENT BEYOND PROGRESSION
This topic is still a subject of discussion. The ESMO Guidelines
state that continuation treatment beyond progression is “an issue
remaining to be defined” (2). In the evidence-based clinical prac-
tice guidelines of the ACCP the second and third-line treatment
after first-line TKI for metastatic NSCLC bearing EGFR mutation
is not discussed (3).
The NCCN Clinical Practice Guidelines of 2013 added an algo-
rithm for treatment of patients who progress on erlotinib. They
suggest that erlotinib can be continued in case of asymptomatic
progression, brain metastasis, or local progression. However, addi-
tional therapy may be added (whole brain radiotherapy, systemic
therapy, local therapy) (21).
In this literature different approaches for treatment beyond
progression are discussed.
TKI CONTINUATION WITH OR WITHOUT CHEMOTHERAPY
Subsequent chemotherapy in patients with EGFR-TKI failure has
been proven to give significant longer OS and PFS than best
supportive care (22).
But should TKI be maintained and combined with chemother-
apy?
The results of a review of Leung and Mok showed no improve-
ment of treatment outcome in EGFR mutation-positive patients,
treated with concurrent combination of chemotherapy and EGFR-
TKI in first-line (23). Since TKI induces a G1-phase cell-cycle
arrest, cell-cycle phase-dependent chemotherapeutic agents will
not be effective during that arrest (24).
In the FASTACT II trial, a phase III trial, the sequential inter-
calated combination of chemotherapy and EGFR-TKI showed
improvement of PFS in first-line treatment of stage IIIb/IV NSCLC
adenocarcinoma bearing the EGFR mutation (25). If the combi-
nation of chemotherapy and TKI in an sequential intercalated
schedule can improve outcome beyond progression is still a topic
of research.
The LUX-Lung 5, a randomized, open label, phase III
trial compared afatinib plus paclitaxel to investigator’s choice
chemotherapy in patients with metastatic NSCLC progressed
on erlotinib/gefitinib and afatinib. The combination showed
improved PFS and objective response rate (ORR) vs. chemother-
apy alone (26).
The IMPRESS trial, a randomized phase III trial evaluating
the addition of gefitinib to cisplatin/pemetrexed as second-line
treatment after gefitinib failure, showed no clinical benefit for the
combination therapy in comparison with doublet chemotherapy
alone (27).
Another possible therapeutic option is to continue TKI without
chemotherapy. This option is mostly used in patients with slowly
or oligo-metastatic disease. For the latter the combination with a
local therapy is preferable.
TKI CONTINUATION WITH LOCAL THERAPY
A retrospective cohort study (28) with 18 patients showed that
local therapy [surgery, radiation therapy, radiofrequency ablation
(RFA)] could be a useful option in case of local progression. In the
evaluated patients, local therapy in combination with continuation
of TKI (restarted TKI within 1 month of local therapy) led to a long
PFS (median time 10 months) and OS (median time 41 months).
Most patients had surgery and only a minority had radiation ther-
apy or RFA. Similar results were seen in a small retrospective study
with nine patients (29), who received radiotherapy in combination
with continuation of TKI, for local disease progression.
Also, for this approach further research is ongoing
(Table 3).
ALTERNATIVE DOSING OR SWITCH TO NEXT-GENERATION TKI
Increasing TKI dosage or switching to another TKI has been
applied in several series of patients and case reports (30, 31).
In general, EGFR-TKIs have a low capacity to penetrate into the
cerebral fluid, although erlotinib achieved a relatively higher level
of CNS penetration. Switching from gefitinib to erlotinib in case
of brain or meningeal progression was applied in a small retro-
spective series of seven patients. Three patients showed partial
response, three had stable disease, and one had progressive dis-
ease. Performance status and symptoms improved in five patients.
The OS from the initiation of erlotinib treatment ranged from 15
to 530 days (median, 88 days) (32). This was not yet confirmed by
larger prospective randomized trials.
Also, increasing the dosage can be beneficial in case of brain or
meningeal progression. One retrospective series showed a partial
response on central nervous system (CNS) radiography in six out
of nine patients after treating with high-dose erlotinib (1500 mg
once weekly), one patient had stable disease, and two had progres-
sive disease. The median time to CNS progression was 2.7 months
(range 0.4–14.5 months) and the median OS was 12 months (range
2.5 – not reached). Further prospective randomized trials are
necessary to confirm this approach (33).
If progression is linked to acquired resistance, no benefit can
be expected from increasing dosage or switching to another
first-generation TKI.
In contrast with erlotinib and gefinitib, second-generation
EGFR-TKIs, such as afatinib, dacomitinib, and neratinib, bind
irreversible with EGFR. They also possess activity against other
HER-family members, like HER2. In the LUX-lung 1 trial, afa-
tinib had a significant longer PFS in comparison with placebo, but
showed no improvement of OS. Furthermore, the trial showed
an important drug-related toxicity in the afatinib-group (34). For
neratinib, a phase II trial showed disappointing results (35) and the
dacomitinib data showed possible benefit in patients with erlotinib
resistance (36), but further investigations are necessary.
In preclinical studies, third-generation EGFR inhibitors
(WZ4002 and CO-1686) showed hopeful results, with activity
against T790M mutations and sparing wild-type EGFR (37–39).
CO-1686, is currently in a phase I/II clinical trial in patients
with EGFR mutated advanced NSCLC that have received prior
EGFR-directed therapy (cfr Table 3). AZD9291 is an irreversible
EGFR-TKI with activity against T790M mutations. A recent phase
I study with AZD9291 showed clinical activity in patients with con-
firmed EGFR T790M mutation NSCLC, with durable responses of
>6 months (40).
COMBINATION THERAPY
In a combinatorial approach, the aim is to inhibit the primary
oncogene in combination with compensatory signaling pathways.
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Table 3 | Overview ongoing trials.
Identifying number (status) Phase Description
TKI±CHEMOTHERAPY
NCT01746277 (recruiting) II Chemotherapy (docetaxel or pemetrexed) sequenced by or combined with gefitinib after progression
NCT01928160 (not yet recruiting) II Chemotherapy (pemetrexed and carboplatin or cisplatin) with or without erlotinib hydrochloride in treating
patient with stage IV non-small cell lung cancer resistant to first-line therapy with erlotinib hydrochloride
or gefitinib
NCT02098954 (not yet recruiting) II Erlotinib combined with chemotherapy (gemcitabine) in TKI-resistant non-small cell lung cancers
NCT01998061 (recruiting) II Continuation of TKI with or without chemotherapy beyond gradual progression
NCT02064491 (recruiting) II Erlotinib treatment with or without chemotherapy beyond progression in EGFR-mutant NSCLC
LOCALTHERAPY
NCT01573702 (recruiting) II Stereotactic radiosurgery or other local ablation followed by erlotinib for patients with epidermal growth
factor receptor (EGFR) mutation who have previously progressed on an epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI)
ALTERNATIVE DOSING OR SWITCHTO NEXT-GENERATIONTKI
NCT01530334 (ongoing) II Iressa re-challenge in advanced NSCLC EGFR M+ patients who responded to gefitinib used as 1st line or
previous treatment (ICARUS)
NCT01932229 (recruiting) II An open label study of BIBW 2992/afatinib in advanced non-small cell lung cancer patients pre-treated
with erlotinib or gefitinib
NCT01526928 (recruiting) I/II CO-1686 (third-generation TKI) in second or third-line treatment for EGFR positive NSCLC, with disease
progression under first or second-generation TKI
COMBINATIONTHERAPY
NCT01982955 (recruiting) I/II MSC2156119J in combination with gefitinib in subjects with MET positive locally advanced or metastatic
non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation and
having acquired resistance to first-line gefitinib
NCT01610336 (recruiting) I/II INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated,
c-MET-amplified non-small cell lung cancer who have progressed after EGFR inhibitor treatment
NCT01900652 (recruiting) II A study of LY2875358 in non-small cell lung cancer participants
NCT01090011 (ongoing) I BIBW 2992 (afatinib) plus cetuximab (Erbitux®) in patients with non-small cell lung cancer with
progression following prior erlotinib (Tarceva®) or gefitinib (Iressa®)
NCT01259089 (ongoing) I/II Hsp90 inhibitor AUY922 and erlotinib hydrochloride in treating patients with stage IIIB-IV non-small cell
lung cancer
NCT01646125 (recruiting) II An open label, randomized phase II study to evaluate the efficacy of AUY922 vs. pemetrexed or docetaxel
in NSCLC patients with EGFR mutations
In a preclinical trial, simultaneous targeting of MET and EGFR in
tumors with MET amplification showed significant tumor regres-
sion (41). Another studied combination therapy is an EGFR-TKI
with the EGFR monoclonal antibody cetuximab. In a phase I/II
trial of cetuximab and afatinib, objective response was observed in
40% of the patients with acquired resistance to erlotinib or gefi-
tinib (42). A phase I/II trial of cetuximab and erlotinib in patients
with lung adenocarcinoma and acquired resistance to erlotinib,
showed no significant activity (43).
Another approach is the inhibition of the heat shock protein
90 (Hsp90). Hsp90 belongs to a family of proteins called mole-
cular chaperones that are involved in the stabilization and fold-
ing of many signaling proteins (collectively referred to as Hsp90
“clients”) that are dysregulated in cancers because this protein is
needed for proper folding of oncogenic kinases. EGFR is one of the
most potent oncogenic client proteins of Hsp90. Several preclini-
cal trials showed good responses in T790M mutation TKI-resistant
model, when a TKI is combined with a Hsp90-inhibitor (44, 45).
Phase I and II trials are ongoing (Table 3).
PRACTICAL MANAGEMENT
A recent review of Cadranel et al. (1) suggests a practical guideline
for patients with an acquired EGFR-TKI resistance. For patients
with primary resistance no guideline was provided due to lack of
evidence-based data.
Progression is defined by mono- or multisite progression or by
rapid or a slow progression. The choice of therapy depends on the
type of progression.
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Rapid progression is most likely induced by resistance mecha-
nisms independent of EGFR signaling pathway or transformation
to small-cell cancer, in contrast with slow progression that is asso-
ciated with EGFR dependent resistance mechanisms. Performing
a re-biopsy is interesting to understand the underlying mechanism
and can guide through the therapeutic options.
For rapidly progressive disease or multi-metastatic dis-
ease, a distinction between transformation to SCLC and non-
EGFR dependent resistance is made. Afterwards the appropriate
chemotherapy or therapeutic trial is selected. For slowly progres-
sive or oligo-metastatic disease, chemotherapy alone is suggested
or TKI with or without loco-regional treatment, with or without
chemotherapy.
CONCLUSION
In the reported cases, patients with EGFR mutation positive
metastatic NSCLC developed locally progressive disease at the
site of the primary tumor after upfront treatment with a TKI for,
respectively, 18, 26, and 40 months.
All three patients were treated with local radiotherapy with
curative dose intent. TKI was temporarily stopped and restarted
after radiotherapy. With this local treatment good disease control
was achieved in all of the patients.
In the first patient, an ongoing disease stabilization is observed.
In the second case, progression was seen 11 months after local
therapy with a pleural effusion, proven to be adenocarcinoma
with EGFR mutation. A switch to systemic chemotherapy was
made, which is supported by the recently presented results of the
important IMPRESS trial. Four months later brain metastasis were
diagnosed which where treated with whole brain radiotherapy
(5 Gy× 4 Gy). Erlotinib was continued afterwards.
The third patient is still without disease progression.
The treatment approach for all the patients is in accordance
with the proposed treatment options in the literature. One can dis-
cuss about the choice between surgery and radiotherapy in cases
with locally progressive disease. In our cases, radiotherapy was
chosen because it is less invasive. Although surgery can offer an
opportunity to obtain new tissue for molecular analysis.
In summary, there are different options for treatment beyond
progression in EGFR mutation positive metastatic NSCLC. The
optimal strategy is still to be defined,but will most probably remain
subject to a personalized approach. Our examples showed that the
combination with local high-dose radiotherapy is feasible and may
be appropriate to control a single site of progression.
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